Cempra (CEMP) Misses Q4 EPS by 1c, to Reduce Workforce

Go back to Cempra (CEMP) Misses Q4 EPS by 1c, to Reduce Workforce

Cempra, Inc. (CEMP) PT Lowered to $4 at Stifel; Reiterates Hold

March 1, 2017 8:59 AM EST

Stifel lowered its price target on Cempra, Inc. (NASDAQ: CEMP) to $4.00 (from $8.00) while maintaining a Hold rating. GAAP net loss of $31.5M, or $(0.60)/share, was wider than Consensus' $(0.55) estimates.

Analyst Stephen Willey commented, "Incremental solithromycin updates provided on managements 4Q16 earnings announcement/call... More

Cempra (CEMP) Underperform Rating Reiterated at Baird Post Q4

February 28, 2017 12:45 PM EST

Jefferies analyst Brian Skorney reiterated his Underperform rating and $2 price target on Cempra, Inc. (NASDAQ: CEMP) following results.

Skorney commented, "Cempra reported in-line earnings in 4Q16, along with a host of trial discontinuations, failure in gonorrhea, and updates on discussions with... More